Clinical Study
A First-In-Human (FIH) Study of Inhibitory Interneurons (NRTX-1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)
NRTX-1001 is a study drug to help people with drug-resistant mesial temporal lobe epilepsy MTLE. We need to learn the safety and effectiveness of NRTX-1001 for it to be approved by the Federal Drug Administration (FDA) and used to help people with MTLE. The information we gain may aid future patients.
For more information contact:
Laura Beeler
laura.beeler@hsc.utah.edu
801-585-9266
IRB#: IRB_00157503
| PI: Amir Arain
| Department: NEUROLOGY
| Approval Date: 2022-11-17 07:00:00
Study Categories: Neurological Studies
| Specialties: Neurology, Neurosurgery
Who can participate?
Gender: All
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria:
- Ages 18 to 65 years old
- Cannot control seizures despite using other study drugs
- Females who may become pregnant must use birth control
- Have at least a 10th-grade education
- Able to read and speak English or Spanish
Exclusion Criteria:
- Epilepsy from another progressive disease
- Another severe medical issue that prevents participation
- Suicide attempt in the past year of participation
- Severe mental health issue(s)
- Pregnant or breast feeding
Will I be paid for my time?
Yes